Influence of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on the digestibility of a dry expanded diet in adult dogs.
The objectives of this study were to evaluate the effects of dirlotapide, a microsomal triglyceride transfer protein inhibitor, on apparent nutrient digestibility of an expanded dry dog food, on defecation frequency and fecal consistency. Eighteen beagles were randomized to either placebo (n = 6) or dirlotapide (n = 12). Testing was divided into a 21-day adaptation phase (days -21 to -1) and a 35-day treatment (digestibility testing) phase (days 0-35). During the treatment phase, dogs were administered oral dirlotapide (0.3 mg/kg) or placebo (0.06 mL/kg) once daily. For digestibility testing, feces were collected over two periods for 7 days each starting on days -9 and 28. All dogs were fed a commercial adult dog food throughout the study. Food intake was adjusted to maintain body weight during adaptation, followed by pair-feeding placebo dogs the amount of food ingested by the dirlotapide dogs during the treatment period. Dogs in both groups had reduced food intake and lost similar amounts of body weight during treatment. Dogs receiving 0.3 mg dirlotapide/kg once daily had a small but significant (P = 0.018) decrease (6.16 +/- 2.22%, mean +/- SD) in crude fat digestibility compared with the placebo-treated food-restricted dogs, but no difference in crude protein, dry matter, or energy digestibility was observed. Fecal consistency and volume and defecation frequency were similar between groups. Dirlotapide effectively reduced appetite and energy intake without affecting nutrient digestibility, except for a minimal decrease in fat digestibility.
Kirk
C A
CA
Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN 37996-4544, USA. ckirk4@utk.edu
Boucher
J F
JF
Sunderland
S J
SJ
Wren
J A
JA
D000284:Administration, Oral; D000821:Animal Feed; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002219:Carbamates / Q000008:administration & dosage / Q000627:therapeutic use*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors*; D004032:Diet; D004063:Digestion; D004283:Dog Diseases / Q000178:diet therapy / Q000188:drug therapy* / Q000473:pathology; D004285:Dogs; D004311:Double-Blind Method; D005260:Female; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000188:drug therapy / Q000662:veterinary*; D011446:Prospective Studies; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D002219:Carbamates; D002352:Carrier Proteins; D007211:Indoles; C106092:microsomal triglyceride transfer protein; C521290:dirlotapide